Midatech Pharma PLC PDMR Dealing (8991O)
07 October 2019 - 5:00PM
UK Regulatory
TIDMMTPH
RNS Number : 8991O
Midatech Pharma PLC
07 October 2019
7 October 2019
Midatech Pharma PLC
("Midatech" or the "Company")
PDMR Dealing
Midatech (AIM: MTPH.L; NASDAQ: MTP), the R&D biotechnology
company focused on delivering innovative oncology and rare disease
products to patients, announces that Stephen Stamp, Chief Financial
Officer and a Director of the Company, has purchased 450,000
ordinary shares of 0.005 pence each in the Company ("Share(s)") at
a price of 6.75 pence per Share.
Following the purchase, Mr Stamp's holding in the Company is
1,000,000 Shares, representing 0.24 per cent. of the Company's
issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Stephen Stamp
--------------------------------- -------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------------------- -------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name Midatech Pharma plc
--------------------------------- -------------------------------------------
b) LEI 549300GKR2G40H3QFY57
--------------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------
a) Description of the Ordinary shares of 0.005 pence each
financial instrument, in Midatech Pharma plc
type of instrument
Identification code GB00BRTL9B63
b) Nature of the transaction Sale and purchase of ordinary shares
--------------------------------- -------------------------------------------
c) Price(s) and volume(s)
------------------------- -------------
Price(s) Volume(s)
------------------------- -------------
6.75p per share 450,000
---------------------------------------------------------------- -------------
d) Aggregated information
- Aggregated volume N/A - single transaction
- Price
e) Date of the transaction 4 October 2019
--------------------------------- -------------------------------------------
f) Place of the transaction London Stock Exchange - AIM
--------------------------------- -------------------------------------------
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR).
For more information, please contact:
Midatech Pharma PLC
Dr Craig Cook, CEO
Stephen Stamp, CFO
Tel: +44 (0)1235 888300
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Tel: +44 (0)20 7886 2500
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Westwicke Partners (US Investor Relations)
Chris Brinzey
Tel: +1 339 970 2843
Email: chris.brinzey@westwicke.com
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ:
MTP) is an R&D company focused on 'Making Medicines Better' by
improving delivery of drugs in the body. The Company combines
existing medications with its proprietary and innovative drug
delivery technologies to provide compelling oncology and rare
disease products that have the potential to powerfully impact the
lives of patients undergoing treatment for life threatening
diseases.
The Company has developed three in-house technology platforms,
each with its own unique mechanism to improve delivery of
medications to sites of disease. All of the Company's technologies
have successfully entered human use in the clinic, providing
important validation of the potential for each platform:
Q-Sphera(TM) platform: a disruptive micro-technology used for
sustained release to prolong and control the release of
therapeutics over an extended period of time (from weeks to
months).
MidaSolve(TM) platform: an innovative nano-technology used to
dissolve insoluble drugs so that they can be administered in liquid
form directly and locally into tumours.
MidaCore(TM) platform: a leading edge nano-technology used for
targeting medications to sites of disease.
By improving biodelivery and biodistribution of approved
existing molecules, Midatech's unique R&D has the potential to
make medicines better, lower technical risks, accelerate regulatory
approval and route to market, and provide newly patentable
products. The platform nature of the technologies allows the
potential to develop multiple drug assets rather than being reliant
on a limited number of programmes.
Midatech's headquarters and R&D facility is in Cardiff, UK,
and manufacturing operation in Bilbao, Spain. For more information
please visit www.midatechpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUSUWRKSARRAA
(END) Dow Jones Newswires
October 07, 2019 02:00 ET (06:00 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From May 2023 to May 2024
